DE60218175D1 - Stabilisierte orale suspensionsformulierung - Google Patents

Stabilisierte orale suspensionsformulierung

Info

Publication number
DE60218175D1
DE60218175D1 DE60218175T DE60218175T DE60218175D1 DE 60218175 D1 DE60218175 D1 DE 60218175D1 DE 60218175 T DE60218175 T DE 60218175T DE 60218175 T DE60218175 T DE 60218175T DE 60218175 D1 DE60218175 D1 DE 60218175D1
Authority
DE
Germany
Prior art keywords
suspension formulation
oral suspension
stabilized oral
stabilized
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60218175T
Other languages
English (en)
Other versions
DE60218175T2 (de
Inventor
Wei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Application granted granted Critical
Publication of DE60218175D1 publication Critical patent/DE60218175D1/de
Publication of DE60218175T2 publication Critical patent/DE60218175T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60218175T 2001-08-06 2002-08-05 Stabilisierte orale suspensionsformulierung Expired - Fee Related DE60218175T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31037201P 2001-08-06 2001-08-06
US310372P 2001-08-06
PCT/US2002/024746 WO2003013473A1 (en) 2001-08-06 2002-08-05 Stabilized oral suspension formulation

Publications (2)

Publication Number Publication Date
DE60218175D1 true DE60218175D1 (de) 2007-03-29
DE60218175T2 DE60218175T2 (de) 2007-11-22

Family

ID=23202195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218175T Expired - Fee Related DE60218175T2 (de) 2001-08-06 2002-08-05 Stabilisierte orale suspensionsformulierung

Country Status (34)

Country Link
US (2) US20030108575A1 (de)
EP (1) EP1414409B1 (de)
JP (1) JP2005500363A (de)
KR (1) KR20040025740A (de)
CN (1) CN1287768C (de)
AP (1) AP1817A (de)
AT (1) ATE353627T1 (de)
BR (1) BR0211736A (de)
CA (1) CA2454173A1 (de)
CO (1) CO5560559A2 (de)
CY (1) CY1106548T1 (de)
DE (1) DE60218175T2 (de)
DK (1) DK1414409T3 (de)
EA (1) EA007901B1 (de)
EC (1) ECSP044974A (de)
ES (1) ES2280560T3 (de)
GE (1) GEP20074027B (de)
HK (1) HK1069542A1 (de)
HR (1) HRP20040118A2 (de)
IL (1) IL159551A0 (de)
IS (1) IS7126A (de)
MA (1) MA27054A1 (de)
MX (1) MXPA04001109A (de)
MY (1) MY135119A (de)
NZ (1) NZ530844A (de)
OA (1) OA12646A (de)
PL (1) PL366382A1 (de)
PT (1) PT1414409E (de)
SI (1) SI1414409T1 (de)
TN (1) TNSN04023A1 (de)
UA (1) UA80682C2 (de)
WO (1) WO2003013473A1 (de)
YU (1) YU7404A (de)
ZA (1) ZA200400639B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20050036956A1 (en) * 2003-08-15 2005-02-17 Lin Fei Non-aqueous liquid tooth whitening composition
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
SI2018153T1 (sl) * 2006-04-26 2012-08-31 Rosemont Pharmaceuticals Ltd Tekoči oralni sestavki
CN100434072C (zh) * 2006-06-19 2008-11-19 西安交通大学 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
WO2009133431A1 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Oral liquid compositions of rhein or diacerein
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
AU2011226523C1 (en) 2010-03-12 2016-07-14 Monsanto Technology Llc Agrochemical gel compositions
PL2575784T3 (pl) * 2010-06-02 2019-03-29 Astellas Deutschland Gmbh Doustne postaci dawkowania bendamustyny
EP2462922A1 (de) * 2010-12-10 2012-06-13 Bioprojet Neue Darreichungsform für Enkephalinasehemmer
CN103379904A (zh) * 2011-01-18 2013-10-30 千寿制药株式会社 具有保存效能的溴芬酸水性液剂组合物
EP2919903B1 (de) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Zusammensetzungen mit einem biologischen wirkstoff und einem nicht geordneten anorganischen oxid
JP2018516279A (ja) * 2015-05-29 2018-06-21 コーダドース・インコーポレーテッド 経口投与用のセレコキシブの液状配合物
EP4353311A3 (de) 2015-07-20 2024-07-17 The Brigham and Women's Hospital, Inc. Scherverdünnende zusammensetzungen als intravaskuläres emboliemittel
CN105902409B (zh) * 2016-05-13 2019-03-05 广东龙湖科技股份有限公司 一种温和且具有触变性的牙膏
EP3528848A4 (de) * 2016-10-19 2020-07-15 Signpath Pharma Inc. Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
CN112402376A (zh) * 2019-08-22 2021-02-26 上海上药信谊药厂有限公司 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法
CN117883379A (zh) * 2021-02-12 2024-04-16 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用
WO2022185338A1 (en) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Stable oral suspension of celecoxib and method of preparation thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
JPH04506216A (ja) * 1989-06-13 1992-10-29 アボツト・ラボラトリーズ 薬物送達用の油を主成分とした非水性液体懸濁液
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
DK0923933T3 (da) * 1993-11-30 2002-10-21 Searle & Co Substituerede pyrazolyl-benzensulfonamider til anvendelse ved behandling af inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
AU2424895A (en) * 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) * 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
ES2139959T3 (es) * 1994-10-27 2000-02-16 Merck Frosst Canada Inc Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5968958A (en) * 1995-01-31 1999-10-19 Merck Frosst Canada, Inc. 5-Methanesulfonamido-3H-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) * 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
CN1174970C (zh) * 1995-05-25 2004-11-10 G·D·瑟尔公司 3-卤代烷基-1h-吡唑的制备方法
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
CA2249009C (en) * 1996-04-12 2003-09-16 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1997046532A1 (en) * 1996-06-03 1997-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4h-isoquinolin-1,3-diones and their use as anti-inflammatory agents
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en) * 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
AU5377698A (en) * 1996-12-10 1998-07-03 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) * 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI9917739B8 (pt) * 1998-04-24 2021-05-25 Merck Sharp & Dohme composto intermediário na preparação de inibidores de cox-2
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
AU2298301A (en) * 1999-10-20 2001-05-08 Board Of Trustees Of Southern Illinois University, The Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
JP2004500427A (ja) * 2000-04-18 2004-01-08 ファルマシア・コーポレーション 選択的シクロオキシゲナーゼ−２阻害薬の即効性製剤
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
GB0617119D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of prognosis

Also Published As

Publication number Publication date
US20030108575A1 (en) 2003-06-12
WO2003013473A1 (en) 2003-02-20
TNSN04023A1 (fr) 2006-06-01
OA12646A (en) 2006-06-16
ZA200400639B (en) 2005-04-08
EA200400148A1 (ru) 2004-08-26
ATE353627T1 (de) 2007-03-15
CA2454173A1 (en) 2003-02-20
NZ530844A (en) 2005-11-25
EA007901B1 (ru) 2007-02-27
AP1817A (en) 2008-01-07
IS7126A (is) 2004-01-26
IL159551A0 (en) 2004-06-01
CO5560559A2 (es) 2005-09-30
UA80682C2 (en) 2007-10-25
PT1414409E (pt) 2007-03-30
DE60218175T2 (de) 2007-11-22
GEP20074027B (en) 2007-02-12
EP1414409A1 (de) 2004-05-06
CN1287768C (zh) 2006-12-06
SI1414409T1 (sl) 2007-06-30
ECSP044974A (es) 2004-03-23
KR20040025740A (ko) 2004-03-25
HK1069542A1 (en) 2005-05-27
CN1549704A (zh) 2004-11-24
MA27054A1 (fr) 2004-12-20
ES2280560T3 (es) 2007-09-16
US20090081309A1 (en) 2009-03-26
JP2005500363A (ja) 2005-01-06
MY135119A (en) 2008-02-29
BR0211736A (pt) 2004-09-28
CY1106548T1 (el) 2012-01-25
MXPA04001109A (es) 2005-02-17
YU7404A (sh) 2006-08-17
EP1414409B1 (de) 2007-02-14
PL366382A1 (en) 2005-01-24
HRP20040118A2 (en) 2004-06-30
DK1414409T3 (da) 2007-06-11
AP2004002969A0 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
ATE289796T1 (de) Orale zusammensetzung
NO20040125L (no) Enterale formuleringer
ATE537831T1 (de) Orale aripiprazol-lösung
ATE319451T1 (de) Tetrahydrochinolin-derivate
NO20033556L (no) Farmasöytiske formuleringer
NO20033384D0 (no) Farmasöytisk formulering
ATE296619T1 (de) Feste orale dosierungsform von simethicon
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20033785L (no) Farmasöytisk formulering
NO20035627D0 (no) Farmasöytisk formulering
DE10196204T1 (de) Orale Vorrichtungen
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ITTO20020789A1 (it) Formulazione solida
DE60326998D1 (de) Orale zubereitung
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
NO20040966L (no) Orale vaksiner.
NO20020524D0 (no) Stabiliserte organisk-peroksid sammensetninger
DE60202381D1 (de) Paroxetin-n-formyl-derivate
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20040454L (no) Stabilisert oral suspensjonformulering.
NO20041236L (no) Farmasoytisk formulering
SE0100199D0 (sv) New formulation
SE0100477D0 (sv) Novel formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee